Mangoceuticals Statistics
Total Valuation
Mangoceuticals has a market cap or net worth of $7.07 million. The enterprise value is $7.19 million.
| Market Cap | 7.07M |
| Enterprise Value | 7.19M |
Important Dates
The next estimated earnings date is Thursday, August 13, 2026, after market close.
| Earnings Date | Aug 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Mangoceuticals has 17.17 million shares outstanding. The number of shares has increased by 377.17% in one year.
| Current Share Class | 17.17M |
| Shares Outstanding | 17.17M |
| Shares Change (YoY) | +377.17% |
| Shares Change (QoQ) | +16.16% |
| Owned by Insiders (%) | 16.15% |
| Owned by Institutions (%) | 4.82% |
| Float | 13.43M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 17.05 |
| Forward PS | n/a |
| PB Ratio | 0.52 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 17.34 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.29, with a Debt / Equity ratio of 0.02.
| Current Ratio | 0.29 |
| Quick Ratio | 0.24 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -169.55 |
Financial Efficiency
Return on equity (ROE) is -113.90% and return on invested capital (ROIC) is -64.40%.
| Return on Equity (ROE) | -113.90% |
| Return on Assets (ROA) | -60.60% |
| Return on Invested Capital (ROIC) | -64.40% |
| Return on Capital Employed (ROCE) | -128.00% |
| Weighted Average Cost of Capital (WACC) | 17.24% |
| Revenue Per Employee | $138,193 |
| Profits Per Employee | -$6.79M |
| Employee Count | 3 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -71.20% in the last 52 weeks. The beta is 2.28, so Mangoceuticals's price volatility has been higher than the market average.
| Beta (5Y) | 2.28 |
| 52-Week Price Change | -71.20% |
| 50-Day Moving Average | 0.39 |
| 200-Day Moving Average | 0.82 |
| Relative Strength Index (RSI) | 55.02 |
| Average Volume (20 Days) | 2,496,718 |
Short Selling Information
The latest short interest is 385,972, so 2.25% of the outstanding shares have been sold short.
| Short Interest | 385,972 |
| Short Previous Month | 268,818 |
| Short % of Shares Out | 2.25% |
| Short % of Float | 2.87% |
| Short Ratio (days to cover) | 0.17 |
Income Statement
In the last 12 months, Mangoceuticals had revenue of $414,579 and -$20.38 million in losses. Loss per share was -$1.56.
| Revenue | 414,579 |
| Gross Profit | 217,323 |
| Operating Income | -17.55M |
| Pretax Income | -19.21M |
| Net Income | -20.38M |
| EBITDA | -15.95M |
| EBIT | -17.55M |
| Loss Per Share | -$1.56 |
Balance Sheet
The company has $174,562 in cash and $294,023 in debt, with a net cash position of -$119,461 or -$0.01 per share.
| Cash & Cash Equivalents | 174,562 |
| Total Debt | 294,023 |
| Net Cash | -119,461 |
| Net Cash Per Share | -$0.01 |
| Equity (Book Value) | 13.47M |
| Book Value Per Share | 0.79 |
| Working Capital | -525,134 |
Cash Flow
| Operating Cash Flow | -4.89M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 1.60M |
| Net Borrowing | 468,500 |
| Free Cash Flow | -4.89M |
| FCF Per Share | -$0.28 |
Margins
| Gross Margin | 52.42% |
| Operating Margin | -4,233.28% |
| Pretax Margin | -4,632.92% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Mangoceuticals does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -377.17% |
| Shareholder Yield | -377.17% |
| Earnings Yield | -288.32% |
| FCF Yield | -69.12% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on October 16, 2024. It was a reverse split with a ratio of 1:15.
| Last Split Date | Oct 16, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:15 |
Scores
Mangoceuticals has an Altman Z-Score of 1.92 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.92 |
| Piotroski F-Score | 2 |